96 results
Page 4 of 5
424B3
a0q7ts96 y81m
2 Aug 21
Prospectus supplement
5:03pm
8-K
EX-3.1
10pfj088bcflu
16 Jul 21
Amendments to Articles of Incorporation or Bylaws
4:01pm
D
5pom5g2
26 May 21
$9.25M in equity, sold $9.25M, 8 investors
12:00am
424B3
lrwyxp
24 May 21
Prospectus supplement
4:38pm
8-K
EX-10.4
agrap6am5nbs hjijc4t
24 May 21
Entry into a Material Definitive Agreement
4:29pm
8-K
EX-10.1
jdfec sdgxn
24 May 21
Entry into a Material Definitive Agreement
4:29pm
8-K
EX-3.1
mssc4avnfwllq qvlx
19 May 21
Clene Appoints David J. Matlin as Chairman of the Board
4:14pm
424B3
3z2c3l5xt89h9oqra
12 May 21
Prospectus supplement
4:43pm
8-K
EX-99.2
b12bpfq
12 May 21
Clene Reports First Quarter 2021 Operating and Financial Highlights
4:14pm
10-Q
8cfjjbr
10 May 21
Quarterly report
5:07pm
424B3
j6t7x
21 Apr 21
Prospectus supplement
6:04am
DEF 14A
qs0gwrcr5 m7rife1
5 Apr 21
Definitive proxy
12:00am
10-K
tl6kllg4fafofqza5
29 Mar 21
Annual report
12:00am
PRE 14A
whscuu0djqv1
18 Mar 21
Preliminary proxy
4:33pm
8-K
EX-99.3
v445y5hs hsx
26 Feb 21
Results of Operations and Financial Condition
5:22pm
S-1
4id9rnmb4 c99b7p
17 Feb 21
IPO registration
12:00am
8-K
EX-10.4
10p8jlwd gr
5 Jan 21
Clene Nanomedicine Closes Merger with Tottenham Acquisition I Limited and Provides Corporate Update
5:18pm
8-K
EX-3.1
nvpo5xw98sukuimw
5 Jan 21
Clene Nanomedicine Closes Merger with Tottenham Acquisition I Limited and Provides Corporate Update
5:18pm
424B3
rxo trgm8
18 Dec 20
Prospectus supplement
2:24pm